Blueprint Medicines Corp. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
43.89 M |
Public Float |
36.97 M |
Blueprint Medicines Corp. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$6.08 |
Market Cap |
$4.68 B |
Shares Outstanding |
48.85 M |
Public Float |
42.04 M |
Address |
45 Sidney Street Cambridge Massachusetts 02139 United States |
Employees | - |
Website | http://www.blueprintmedicines.com |
Updated | 07/08/2019 |
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia. |